About Icardio.Ai
iCardio.ai is a Los Angeles-based company pioneering the application of artificial intelligence to echocardiography and ultrasound interpretation. The company has developed a comprehensive suite of AI-powered tools designed to automate and enhance the analysis of cardiac ultrasound imaging. Leveraging a database of over 200 million individual echocardiographic images from hundreds of thousands of de-identified patients, iCardio.ai builds machine learning algorithms that address the significant challenges in cardiac imaging interpretation. The company's flagship products include EchoMeasure™, an FDA 510(k)-cleared solution that automates over a dozen standard cardiac measurements including ejection fraction, chamber dimensions, and wall thickness assessments. CardioVision™, which has received both FDA 510(k) clearance and FDA Breakthrough Device Designation, automatically detects aortic stenosis from parasternal long axis clips, addressing a critical diagnostic need in cardiovascular care. Additional tools include EchoCheck for image quality assessment, EchoGPT for image-to-text analysis, and various quantitative and qualitative interpretation modules. iCardio.ai partners with ultrasound equipment manufacturers and PACS providers to integrate its technology directly into clinical workflows. The company collaborates with world-leading cardiologists and AI scientists to create comprehensive automated analysis of echocardiograms at an unprecedented scale. Their solutions aim to reduce inter-reader variability, minimize work-related musculoskeletal disorders among sonographers, and ensure that critical conditions like aortic stenosis are never missed. The company serves health systems, cardiology practices, and imaging centers, with integrations available through major PACS systems including UltraLinQ.
Mission & Story
Mission
We are on a mission to automate Ultrasound with artificial intelligence
Founding Story
Founded through a collaboration of world-leading cardiologists and AI scientists to combat the high dependency on doctor availability and the prevalence of false positives and negatives in echocardiogram interpretation. The company was created to address heart disease, the leading cause of death in the United States, by producing comprehensive AI-driven analysis of echocardiograms on an unprecedented scale.
Clinical Focus
Medical conditions and clinical areas addressed by Icardio.Ai.
Who It Serves
Milestones & Awards
Recent Milestones
FDA 510(k) clearance for CardioVision™ for Aortic Stenosis (November 2024); FDA Breakthrough Device Designation for CardioVision™; Partnership with UltraLinQ PACS (January 2024); Second FDA 510(k) clearance received
Awards & Recognition
FDA Breakthrough Device Designation for CardioVision™
Key Partnerships
%20Clearance.png){kind=spacer}
Company Details
- Headquarters
- Los Angeles, CA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Anumana AI
series c · 175 employees
Anumana AI develops and delivers AI-driven ECG algorithms to enable early diagnosis and intervention for cardiovascular conditions.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.